Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glumetinib plus Osimertinib vs Chemo in EGFR-TKI Resistant NSCLC with MET Alterations
NCT06829459Phase 3Recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Feb 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of glumetinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Apr 2025; status: recruiting.
02
Drugs
glumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06829459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06829459.